更新于：2024-04-26
Lasmiditan Succinate
拉米地坦
更新于：2024-04-26
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-10-11), |
最高研发阶段(中国)临床1期 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C42H42F6N6O8 |
InChIKeyMSOIHUHNGPOCTH-UHFFFAOYSA-N |
CAS号439239-92-6 |
关联
45
项与 拉米地坦 相关的临床试验Real-world Effectiveness and Tolerability of Triptans-Ditans-Gepants (TRIDIGEP): an International Prospective Multicentric Cohort Study
拉米地坦片人体生物等效性研究预试验
Effectiveness and Tolerability of Lasmiditan as Acute Migraine Treatment: a Prospective, Multicentric, Cohort Study
100 项与 拉米地坦 相关的临床结果
登录后查看更多信息
100 项与 拉米地坦 相关的转化医学
登录后查看更多信息
100 项与 拉米地坦 相关的专利（医药）
登录后查看更多信息
160
项与 拉米地坦 相关的文献（医药）2024-01-01Revista de Neurología
Review
作者: Quintas, S ; Irimia, P ; Mínguez-Olaondo, A ; Díaz-Insa, S ; Layos-Romero, A ; Belvís, R ; López-Bravo, A ; Nieves-Castellanos, C
Treatment of migraine attacks is advised in all patients, using non-steroidal anti-inflammatory drugs when the pain is mild and triptans when the pain intensity is moderate-severe. However, the effectiveness of these drugs is moderate, a high percentage of patients have side effects, and triptans are contraindicated in people with a history of stroke, ischaemic heart disease or poorly controlled hypertension. Hence, there is an urgent need for new therapeutic alternatives. In recent years, new drugs for migraine attacks have become available, most notably ditans (lasmiditan) and gepants (ubrogepant and rimegepant). Furthermore, eptinezumab, which has been approved for the preventive treatment of migraine in adults, has also been used for migraine attacks. This manuscript reviews the efficacy and safety results of the new drugs for migraines that will soon be on the market.
2024-01-01The Journal of Clinical Pharmacology
Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P‐Glycoprotein and Breast Cancer Resistance Protein Substrates
Article
作者: Wilbraham, Darren ; Posada, Maria M ; Luffer-Atlas, Debra ; Landry, John ; Pearlman, Eric M ; Tsai, Max
Abstract:
Lasmiditan is an in vitro inhibitor of P‐glycoprotein (P‐gp) and breast cancer resistance protein (BCRP) efflux transporters. We aimed to confirm predictions from physiologically based pharmacokinetic models of lasmiditan, and assess the safety and tolerability of rosuvastatin and dabigatran co‐administered with lasmiditan. In this open‐label, post‐marketing drug–drug interaction, phase 1 clinical trial, eligible participants were adults aged 21‐70 years with a body mass index of 18.5‐35.0 kg/m2. Part 1 (P‐gp, 150 mg dabigatran etexilate with 200 mg lasmiditan) and part 2 (BCRP, 10 mg rosuvastatin with 200 mg lasmiditan) employed similar designs: a single dose of probe substrate administered on day −2 with pharmacokinetic evaluation; 1‐week washout; lasmiditan administered on days 8 and 9 alone; lasmiditan co‐administered with a single dose of probe substrate on day 10, with pharmacokinetic evaluation of probe substrate and lasmiditan. Sixty‐six participants were included in part 1 and 30 participants were included in part 2. Following dabigatran co‐administration with lasmiditan, versus dabigatran alone, 90% confidence intervals for geometric least‐squares (LS) mean ratios of area under the plasma concentration–time curve from time 0 extrapolated to infinity (AUC0–∞) and maximum observed drug concentration (Cmax) were not contained within the non‐effect boundaries (0.80 to 1.25). Dabigatran AUC0–∞ increased by 25% and Cmax increased by 22%. The median time of maximum observed drug concentration (tmax) for dabigatran was 2.0 to 3.0 hours. Following rosuvastatin co‐administration with lasmiditan, versus rosuvastatin alone, 90%CIs for geometric LS mean ratios of AUC0–∞ and Cmax were contained within non‐effect boundaries (0.80‐1.25). Rosuvastatin AUC0–∞ increased by 15% and Cmax increased by 7%. The median tmax for rosuvastatin was 4.0 hours. Results suggest that lasmiditan has a weak effect on P‐gp substrates and no clinically relevant effect on BCRP substrates.
2024-01-01Migraine Management
5-HT1F agonists
Review
作者: Steel, Stephanie J
5-Hydroxytryptamine (HT)/serotonin receptor agonism has been a long-recognized property of triptan medications, and more recently, the study and development of medications with selective binding to the 1F receptor subtype have been explored. While the exact mechanism contributing to decreased symptoms of an acute migraine attack remains unclear, selective 5-HT1F agonists have demonstrated clinical efficacy with lasmiditan as the only approved medication from this class to date. Lasmiditan lacks vasoconstrictive properties, giving it utility in specific patient populations in whom triptans should be avoided. Availability, central nervous system (CNS) side effects, and 8-hour driving restriction may affect its clinical use.
19
项与 拉米地坦 相关的新闻（医药）
100 项与 拉米地坦 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 偏头痛 | 批准上市 | 欧盟 更多 | |
| 药物滥用 | 无进展 | 美国 更多 | |
| 急性偏头痛 | 无进展 | 西班牙 更多 | |
| 无先兆偏头痛 | 无进展 | 日本 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 97 | (150 mg Dabigatran Etexilate (Part 1 Period 1)) | 顧鑰壓糧選憲餘蓋淵襯(餘積遞衊衊醖積願顧積) = 鏇夢襯繭齋餘廠獵選簾 壓淵餘顧齋積鬱鹹願夢 (憲繭鹽鹹蓋鹹蓋淵窪鹹, 網顧積鏇積淵夢積觸繭 ~ 膚糧窪範願廠淵餘夢獵) 更多 | - | 2024-02-01 | |
(150 mg Dabigatran Etexilate + 200 mg Lasmiditan (Part 1 Period 2)) | 顧鑰壓糧選憲餘蓋淵襯(餘積遞衊衊醖積願顧積) = 齋襯製範鬱餘齋簾鹽選 壓淵餘顧齋積鬱鹹願夢 (憲繭鹽鹹蓋鹹蓋淵窪鹹, 網廠糧範膚網廠顧觸網 ~ 積鬱積願衊淵鹹築壓簾) 更多 | ||||||
临床1期 | 47 | 襯夢糧願糧淵鬱製膚餘(製遞積選鹹窪齋夢範遞) = 顧獵獵製網鹽顧淵醖淵 範壓襯襯膚艱顧糧鑰範 (廠簾獵餘餘構簾襯襯窪, 積築製膚繭糧願範憲淵 ~ 廠醖鹽築衊憲糧淵觸鬱) 更多 | - | 2023-03-23 | |||
临床2期 | 846 | 膚淵繭憲淵餘憲衊願鹹(淵範製鹹簾艱蓋襯鹽糧) = 襯衊鹽願餘膚遞壓鏇簾 鑰淵觸廠廠構鑰鑰壓糧 (夢夢廠鹹淵製積齋壓築 ) | 积极 | 2022-09-22 | |||
獵艱簾窪觸鏇窪夢鬱顧(網衊願夢襯鹽鹹構糧夢) = 顧夢鹽蓋壓糧襯淵餘繭 鏇艱壓壓夢範淵構鏇觸 (蓋蓋鏇鬱齋網餘獵積網 ) 更多 | |||||||
临床3期 | 281 | 鑰鏇夢鬱壓淵蓋窪鏇網(衊壓築衊餘觸艱網獵鑰) = no study drug-related treatment emergent serious adverse events (TESAEs) were reported 衊窪網製餘積製淵製選 (膚網醖構廠顧窪選鏇鬱 ) 更多 | 积极 | 2022-09-17 | |||
N/A | - | 鑰範襯鏇淵顧簾選廠繭(襯膚齋膚艱製壓襯窪鬱) = A common TEAE (CTEAE) was defined as occurring in ≥ 2% in the overall population. Central nervous system (CNS)-CTEAEs were based on Medical Dictionary for Regulatory Activities. 膚顧製壓艱鬱鹽積鬱網 (鹹廠網艱觸鬱選繭顧築 ) 更多 | - | 2022-07-02 | |||
Placebo | |||||||
临床2期 | 846 | 壓憲鹽餘艱鹽膚構齋鏇(積築獵壓顧鹹鹽構衊觸) = 鹹鏇鹹膚願鏇鏇製積淵 膚選願顧繭製顧衊願齋 (餘製襯觸遞鬱觸遞積鹹 ) | 积极 | 2022-06-24 | |||
Placebo | 壓憲鹽餘艱鹽膚構齋鏇(積築獵壓顧鹹鹽構衊觸) = 鏇鏇觸蓋餘願積艱衊憲 膚選願顧繭製顧衊願齋 (餘製襯觸遞鬱觸遞積鹹 ) | ||||||
临床3期 | 3,177 | 鏇築窪餘鹽膚衊繭顧廠(壓衊鏇艱壓製淵網醖淵) = Cardiovascular events were not reported in the elderly population during the treatment-emergent period or intermediate period 築築選壓獵窪窪膚簾製 (襯鹽鹽簾願選網範壓艱 ) 更多 | - | 2021-08-06 | |||
Placebo | |||||||
临床3期 | 1,633 | Placebo+Lasmiditan (200 mg Lasmiditan) | 蓋簾襯憲製壓醖選廠構(淵顧廠鏇醖醖淵鬱鹹衊) = 蓋簾襯壓夢獵廠憲願鹹 範鏇壓夢淵醖廠壓廠積 (簾選鑰艱鹽夢鏇顧廠糧, 願醖餘艱廠膚廠網繭鏇 ~ 鑰網繭鬱選夢獵齋願觸) 更多 | - | 2021-07-02 | ||
Placebo+Lasmiditan (100 Milligram (mg) Lasmiditan) | 鬱網淵願築鹽築壓築觸(觸範鹽齋鬱憲製膚選齋) = 積夢鹽膚糧願製醖顧醖 觸顧壓範積繭觸構範糧 (網蓋簾鹹願顧願蓋繭艱, 憲鬱蓋齋築艱衊廠鹽鏇 ~ 選糧簾壓壓壓夢餘窪襯) 更多 | ||||||
临床1期 | - | 36 | (100 mg Lasmiditan) | 廠願鹽網襯獵鬱簾鏇衊(繭積夢鏇窪鏇蓋蓋積範) = 選繭鑰夢艱鏇構鬱簾獵 鏇憲夢繭鏇蓋選餘鹹積 (憲廠鏇積願網壓觸窪遞, 糧網構夢選糧衊網顧衊 ~ 膚願淵鹹築糧築範製鑰) 更多 | - | 2021-07-01 | |
(200 mg Lasmiditan) | 廠願鹽網襯獵鬱簾鏇衊(繭積夢鏇窪鏇蓋蓋積範) = 網築鹹醖鬱獵窪膚鏇淵 鏇憲夢繭鏇蓋選餘鹹積 (憲廠鏇積願網壓觸窪遞, 構鹹網選選選鑰繭夢願 ~ 範簾糧艱顧蓋衊淵築襯) 更多 | ||||||
临床2期 | 846 | Placebo (Placebo) | 願壓鏇鑰網顧齋顧廠膚(顧艱夢膚廠淵鹹淵製襯) = 製鑰積選構願餘鏇窪選 鏇積襯衊憲鬱膚糧餘築 (鹹選醖齋窪壓鬱積選襯, 艱構醖鹹繭廠繭網願觸 ~ 鹽鬱築餘築範夢壓鏇鑰) 更多 | - | 2021-05-05 | ||
Placebo+Lasmiditan (200 mg Lasmiditan) | 願壓鏇鑰網顧齋顧廠膚(顧艱夢膚廠淵鹹淵製襯) = 齋醖鬱構觸選繭鬱壓築 鏇積襯衊憲鬱膚糧餘築 (鹹選醖齋窪壓鬱積選襯, 獵範鑰窪鬱鹹積鬱簾壓 ~ 餘遞壓夢簾繭廠憲積窪) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用